Fulgent Genetics, Inc.
FLGTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeFulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. Valued at $553.1M, FLGT is a small-cap name in its sector. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Market Cap
$553.1M
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-14.57
EPS (TTM)
$-2.82
EPS (Fwd)
$-1.38
ROE
-8.1%
ROA
-6.3%
Cash
$257.0M
Total Debt
$9.6M
Free CF
-$90.9M
52W Change
-13.8%
Annual Financials
Cash vs Debt
Where FLGT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, FLGT finished 6.91% above its 150-day moving average ($18.53) and 0.56% above its 200-day moving average ($19.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FLGT overbought or oversold?
At the October 19, 2026 close, FLGT's RSI(14) was 33.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Fulgent Genetics, Inc. holds $257.0M in cash against $9.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$90.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -8.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $619.0M (2022) to $322.7M (2025), a 48% decline worth watching.
With cash comfortably exceeding debt, FLGT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FLGT.